Daiichi Sankyo
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
The study includes 2 independent substudies, which have been defined by treatment combination and participant population as follows: 1. Substudy 1 will evaluate the safety and efficacy of DS-3939a in combination with immunotherapy with or without chemotherapy (carboplatin or pemetrexed) in participants with locally advanced unresectable or metastatic non-squamous (NSQ) NSCLC in the first-line setting. 2. Substudy 2 will evaluate the safety and efficacy of DS-3939a in combination with DS-1103a or as a monotherapy in participants with locally advanced unresectable or metastatic NSQ NSCLC who ar…
Inclusion Criteria: 1. Sign and date the Main Trial informed consent form (ICF), prior to the start of any trial-specific procedures. 2. Adults greater than or equal to (≥)18 years of age at the time the Main Trial ICF is signed (follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old). 3. Histologically documented Stage IIIB, IIIC disease who is not candidate for surgical resection or definitive chemoradiation, or Stage IV NSQ NSCLC. 4. Has a left ventricular ejection fraction (LVEF) ≥50 percent (%) by either an echocardiogram (ECHO) or mult…
DS-3939a will be administered as an IV infusion.
Pembrolizumab will be administered as an IV infusion.
Carboplatin will be administered as an IV infusion.
Pemetrexed will be administered as an IV infusion.
DS-1103a will be administered as an IV infusion.